Cargando…

Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids

SUMMARY: Of patients prescribed systemic glucocorticoids, this study identifies the proportion prescribed osteoporosis pharmacologic treatment and associated characteristics. Overall, 13.2% of patients were prescribed osteoporosis pharmacologic treatment. Predictors included documented osteoporosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Billups, Sarah J., Thai, Vinh K, Denkins, Jacob, Dettman, Ian C., Rothman, Micol S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976654/
https://www.ncbi.nlm.nih.gov/pubmed/36856881
http://dx.doi.org/10.1007/s11657-023-01222-0
_version_ 1784899130165821440
author Billups, Sarah J.
Thai, Vinh K
Denkins, Jacob
Dettman, Ian C.
Rothman, Micol S.
author_facet Billups, Sarah J.
Thai, Vinh K
Denkins, Jacob
Dettman, Ian C.
Rothman, Micol S.
author_sort Billups, Sarah J.
collection PubMed
description SUMMARY: Of patients prescribed systemic glucocorticoids, this study identifies the proportion prescribed osteoporosis pharmacologic treatment and associated characteristics. Overall, 13.2% of patients were prescribed osteoporosis pharmacologic treatment. Predictors included documented osteoporosis, past DXA or fracture, and provision of care within a department using embedded protocols, suggesting electronic medical record-based tools may be beneficial. PURPOSE: This study aimed to identify a cohort of patients at risk for glucocorticoid-induced osteoporosis based on their prescribed glucocorticoid regimens and to quantify the proportion who were also prescribed osteoporosis pharmacologic treatment. The secondary objective was to recognize patient characteristics associated with receiving such treatment. METHODS: A retrospective single-site cohort study used prescription order data to identify 7774 adults prescribed chronic glucocorticoids and measure the proportion also prescribed osteoporosis pharmacologic treatment. RESULTS: Of the total cohort, 1026/7774 (13.2%) had osteoporosis pharmacologic treatment prescribed. Of the subgroups prescribed a prednisone-equivalent of 5, 10, or 20 mg per day or more for at least 180 days, 584/4262 (13.7%), 153/1048 (14.6%), and 47/344 (13.7%) had treatment prescribed. Factors independently associated with osteoporosis pharmacologic treatment initiation included having osteoporosis or osteopenia on the problem list (OR = 4.45, 95% CI 3.70–5.34), history of dual-energy X-ray absorptiometry (DXA) screening (OR = 2.18, 95% CI 1.82–2.62), history of fracture (OR = 1.83, 95% CI 1.54–2.167), and longer duration of glucocorticoid use (OR = 1.33, 95% CI 1.10–1.59). The prescribing department was also a significant predictor of medication initiation, with cardiac transplant (OR = 6.04, 95% CI 3.97–9.17), oncology (OR = 4.11, OR 3.28–5.14), and lung transplant (OR = 1.51, 95% CI 1.08, 2.12) being positively correlated with this outcome, and nephrology (OR = 0.51, 95% CI 0.36–0.72) and kidney transplant (OR = 0.53, 95% CI 0.37, 0.75) being negatively correlated. CONCLUSION: Prescribing rate of osteoporosis pharmacologic treatment in patients using chronic glucocorticoids is low. Examining practices with higher prescribing rates may offer insight into improving protection against osteoporosis-induced fractures.
format Online
Article
Text
id pubmed-9976654
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-99766542023-03-02 Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids Billups, Sarah J. Thai, Vinh K Denkins, Jacob Dettman, Ian C. Rothman, Micol S. Arch Osteoporos Short Communication SUMMARY: Of patients prescribed systemic glucocorticoids, this study identifies the proportion prescribed osteoporosis pharmacologic treatment and associated characteristics. Overall, 13.2% of patients were prescribed osteoporosis pharmacologic treatment. Predictors included documented osteoporosis, past DXA or fracture, and provision of care within a department using embedded protocols, suggesting electronic medical record-based tools may be beneficial. PURPOSE: This study aimed to identify a cohort of patients at risk for glucocorticoid-induced osteoporosis based on their prescribed glucocorticoid regimens and to quantify the proportion who were also prescribed osteoporosis pharmacologic treatment. The secondary objective was to recognize patient characteristics associated with receiving such treatment. METHODS: A retrospective single-site cohort study used prescription order data to identify 7774 adults prescribed chronic glucocorticoids and measure the proportion also prescribed osteoporosis pharmacologic treatment. RESULTS: Of the total cohort, 1026/7774 (13.2%) had osteoporosis pharmacologic treatment prescribed. Of the subgroups prescribed a prednisone-equivalent of 5, 10, or 20 mg per day or more for at least 180 days, 584/4262 (13.7%), 153/1048 (14.6%), and 47/344 (13.7%) had treatment prescribed. Factors independently associated with osteoporosis pharmacologic treatment initiation included having osteoporosis or osteopenia on the problem list (OR = 4.45, 95% CI 3.70–5.34), history of dual-energy X-ray absorptiometry (DXA) screening (OR = 2.18, 95% CI 1.82–2.62), history of fracture (OR = 1.83, 95% CI 1.54–2.167), and longer duration of glucocorticoid use (OR = 1.33, 95% CI 1.10–1.59). The prescribing department was also a significant predictor of medication initiation, with cardiac transplant (OR = 6.04, 95% CI 3.97–9.17), oncology (OR = 4.11, OR 3.28–5.14), and lung transplant (OR = 1.51, 95% CI 1.08, 2.12) being positively correlated with this outcome, and nephrology (OR = 0.51, 95% CI 0.36–0.72) and kidney transplant (OR = 0.53, 95% CI 0.37, 0.75) being negatively correlated. CONCLUSION: Prescribing rate of osteoporosis pharmacologic treatment in patients using chronic glucocorticoids is low. Examining practices with higher prescribing rates may offer insight into improving protection against osteoporosis-induced fractures. Springer London 2023-03-01 2023 /pmc/articles/PMC9976654/ /pubmed/36856881 http://dx.doi.org/10.1007/s11657-023-01222-0 Text en © International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Short Communication
Billups, Sarah J.
Thai, Vinh K
Denkins, Jacob
Dettman, Ian C.
Rothman, Micol S.
Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
title Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
title_full Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
title_fullStr Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
title_full_unstemmed Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
title_short Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
title_sort bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976654/
https://www.ncbi.nlm.nih.gov/pubmed/36856881
http://dx.doi.org/10.1007/s11657-023-01222-0
work_keys_str_mv AT billupssarahj badtothebonesprescribingofdrugsforthepreventionandtreatmentofosteoporosisinpatientsonchronicglucocorticoids
AT thaivinhk badtothebonesprescribingofdrugsforthepreventionandtreatmentofosteoporosisinpatientsonchronicglucocorticoids
AT denkinsjacob badtothebonesprescribingofdrugsforthepreventionandtreatmentofosteoporosisinpatientsonchronicglucocorticoids
AT dettmanianc badtothebonesprescribingofdrugsforthepreventionandtreatmentofosteoporosisinpatientsonchronicglucocorticoids
AT rothmanmicols badtothebonesprescribingofdrugsforthepreventionandtreatmentofosteoporosisinpatientsonchronicglucocorticoids